Chapter 20 References 
            Alarcon GS, Friedman AW, Straaton KV, et al. Systemic lupus erythematosus in three ethnic 
            groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. 
            LUpus in MInority populations: NAture vs. Nurture. Lupus 1999;8:197–209. 
            Alarcon GS, Roseman J, Bartolucci AA, et al. Systemic lupus erythematosus in three ethnic 
            groups: II. Features predictive of disease activity early in its course. LUMINA Study Group. Lupus 
            in minority populations, nature versus nurture. Arthritis Rheum 1998;41:1173–80. 
            Alonso MD, Llorca J, Martinez-Vazquez F, et al. Systemic lupus erythematosus in northwestern 
            Spain: a 20-year epidemiologic study. Medicine (Baltimore) 2011;90:350–8. 
            Ardoin SP, Schanberg LE; et al. The management of pediatric systemic lupus erythematosus. Nat 
            Clin Pract Rheumatol 2005;1:89–92. 
            Asanuma Y, Oeser A, Shintani AK, et al. Premature coronary-artery atherosclerosis in systemic 
            lupus erythematosus. N Engl J Med 2003;349:2407–2415. 
            *Bertsias, G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of 
            systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for 
            International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008;67:195–205. 
            *Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommendations for the management of 
            systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the 
            EULAR standing committee for clinical affairs. Ann Rheum Dis 2010a;69:2074–82. 
            Bertsias GK, Nakou M, Choulaki C, et al. Genetic, immunologic, and immunohistochemical 
            analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus 
            erythematosus. Arthritis Rheum 2009;60:207–18. 
            *Bertsias GK, Pamfil C, Fanouriakis A, et al. Diagnostic criteria for systemic lupus erythematosus: 
            has the time come? Nat Rev Rheumatol 2013;9:687–94. 
            Bertsias GK, Salmon JE, Boumpas DT, et al. Therapeutic opportunities in systemic lupus 
            erythematosus: state of the art and prospects for the new decade. Ann Rheum Dis 
            2010b;69:1603–11. 
            Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and 
            European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) 
            recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 
            2012;71:1771–82. 
            Biesecker G, Lavin L, Ziskind M, et al. Cutaneous localization of the membrane attack complex in 
            discoid and systemic lupus erythematosus. N Engl J Med 1982;306:264–70. 
            Birnbaum J, Petri M, Thompson R, et al. Distinct subtypes of myelitis in systemic lupus 
            erythematosus. Arthritis Rheum 2009;60:3378–87. 
            Bodolay E, Csiki Z, Szekanecz Z, et al. Five-year follow-up of 665 Hungarian patients with 
            undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol 2003;21:313–20. 
            Bosch X, Guilabert A, Pallarés L, et al. Infections in systemic lupus erythematosus: a prospective 
            and controlled study of 110 patients. Lupus 2006;15:584–9.                                      1 
            EULAR Secretariat | Seestrasse 240 | 8802 Kilchberg | Switzerland  
            T: +41 44 716 30 30 | F: +41 44 716 30 39  
            M: eular@eular.org | W: www.eular.org  
                                                                     
        Bresnihan B. Outcome and survival in systemic lupus erythematosus. Ann Rheum Dis 
        1989;48:443–5. 
        Bruce IN, Gladman DD, Urowitz MB, et al. Premature atherosclerosis in systemic lupus 
        erythematosus. Rheum Dis Clin North Am 2000;26:257–78. 
        Bukhari M. Drug-induced rheumatic diseases: a review of published case reports from the last two 
        years. Curr Opin Rheumatol 2012;24:182–6. 
        Calvo-Alen J, Alarcon GS, Burgard SL, et al. Systemic lupus erythematosus: predictors of its 
        occurrence among a cohort of patients with early undifferentiated connective tissue disease: 
        multivariate analyses and identification of risk factors. J Rheumatol 1996;23:469–75. 
        Cardoso CR, Signorelli FV, Papi JA, et al. Initial and accrued damage as predictors of mortality in 
        Brazilian patients with systemic lupus erythematosus: a cohort study. Lupus 2008;17:1042–8. 
        Cervera R, Abarca-Costalago M, Abramovicz D, et al. Systemic lupus erythematosus in Europe at 
        the change of the millennium: lessons from the Euro-Lupus Project. Autoimmun Rev 2006;5:180–
        6. 
        Cervera R, Khamashta MA. Epidemiology of systemic lupus erythematosus at the change of the 
        millennium: lessons from the Euro-Lupus and the LUMINA projects. Lupus 2006;15:1–2. 
        Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic 
        patterns of disease expression in a cohort of 1,000 patients. The European Working Party on 
        Systemic Lupus Erythematosus. Medicine (Baltimore) 1993;72:113–24. 
        *Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus 
        during a 5-year period. A multicentre prospective study of 1,000 patients. European Working Party 
        on Systemic Lupus Erythematosus. Medicine (Baltimore) 1999;78:167–75. 
        Cervera R, Khamashta MA, Font J, et al. European Working Party on Systemic Lupus 
        Erythematosus: a 10 year report. Lupus 2001;10:892–4. 
        Cervera R, Khamashta MA, Hughes GR. The Euro-lupus project: epidemiology of systemic lupus 
        erythematosus in Europe. Lupus 2009;18:869–74. 
        Chambers SA, Allen E, Rahman A, et al. Damage and mortality in a group of British patients with 
        systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford) 
        2009;48:673–5. 
        Chen MJ, Tseng HM, Huang YL, et al. Long-term outcome and short-term survival of patients with 
        systemic lupus erythematosus after bacteraemia episodes: 6-yr follow-up. Rheumatology (Oxford) 
        2008;47:1352–7. 
        Cooper GS, Wither J, Bernatsky S, et al. Occupational and environmental exposures and risk of 
        systemic lupus erythematosus: silica, sunlight, solvents. Rheumatology (Oxford) 2010;49:2172–80. 
        Dias AM, do Couto MC, Duarte CC, et al. White blood cell count abnormalities and infections in 
        one-year follow-up of 124 patients with SLE. Ann NY Acad Sci 2009;1173:103–7. 
        Faust TW, Chang EH, Kowal C, et al. Neurotoxic lupus autoantibodies alter brain function through 
        two distinct mechanisms. Proc Natl Acad Sci USA 2010;107:18569–74. 
                                                                   2 
        EULAR Secretariat | Seestrasse 240 | 8802 Kilchberg | Switzerland  
        T: +41 44 716 30 30 | F: +41 44 716 30 39  
        M: eular@eular.org | W: www.eular.org  
                                                                     
        Feng PH, Lin SM, Yu CT, et al. Inadequate antimicrobial treatment for nosocomial infection is a 
        mortality risk factor for systemic lupus erythematous patients admitted to intensive care unit. Am J 
        Med Sci 2010;340:64–8. 
        Fremeaux-Bacchi V, Miller EC, Liszewski MK, et al. Mutations in complement C3 predispose to 
        development of atypical hemolytic uremic syndrome. Blood 2008;112:4948–4952. 
        Futrell N, Millikan C. Frequency, aetiology, and prevention of stroke in patients with systemic lupus 
        erythematosus. Stroke 1989;20:583–91. 
        Gilliam JN, Sontheimer RD. Skin manifestations of SLE. Clin Rheum Dis 1982;8:207–18. 
        Goldblatt F, Chambers S, Rahman A, et al. Serious infections in British patients with systemic 
        lupus erythematosus: hospitalisations and mortality. Lupus 2009;18:682–9. 
        Griffiths B, Mosca M, Gordon C. Assessment of patients with systemic lupus erythematosus and 
        the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 2005;19:685–708. 
        Guballa N, Sammaritano L, Schwartzman S, et al. Ovulation induction and in vitro fertilization in 
        systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum 2000;43:550–6. 
        Guerra SG, Vyse TJ, Cunninghame Graham DS. The genetics of lupus: a functional perspective. 
        Arthritis Res Ther 2012;14:211. 
        Hiraki LT, Feldman CH, Liu J, et al. Prevalence, incidence, and demographics of systemic lupus 
        erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid 
        beneficiary population. Arthritis Rheum 2012;64: 2669–76. 
        *Hochberg MC. Updating the American College of Rheumatology revised criteria for the 
        classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725. 
        Javierre BM, Fernandez AF, Richter J, et al. Changes in the pattern of DNA methylation associate 
        with twin discordance in systemic lupus erythematosus. Genome Res 2010;20:170–9. 
        Jeong SJ, Choi H, Lee HS, et al. Incidence and risk factors of infection in a single cohort of 110 
        adults with systemic lupus erythematosus. Scand J Infect Dis 2009;41:268–274. 
        Jimenez S, Cervera R, Font J, et al. The epidemiology of systemic lupus erythematosus. Clin Rev 
        Allergy Immunol 2003;25:3–12. 
        Jonsson R, Heyden G, Westberg NG, et al. Oral mucosal lesions in systemic lupus erythematosus-
        -a clinical, histopathological and immunopathological study. J Rheumatol 1984;11:38–42. 
        Kitagawa Y, Gotoh F, Koto A, et al. Stroke in systemic lupus erythematosus. Stroke 1990;21:1533–
        9. 
        Kojima E, Naito K, Iwai M, et al. Antiphospholipid syndrome complicated by thrombosis of the 
        superior mesenteric artery, co-existence of smooth muscle hyperplasia. Intern Med 1997;36:528–
        31. 
        Kowal C, Degiorgio LA, Lee JY, et al. Human lupus autoantibodies against NMDA receptors 
        mediate cognitive impairment. Proc Natl Acad Sci USA 2006;103:19854–9. 
        Lee JG, Joo KW, Chung WK, et al. Diffuse alveolar haemorrhage in lupus nephritis. Clin Nephrol 
        2001;55:282–8.                                             3 
        EULAR Secretariat | Seestrasse 240 | 8802 Kilchberg | Switzerland  
        T: +41 44 716 30 30 | F: +41 44 716 30 39  
        M: eular@eular.org | W: www.eular.org  
                                                                     
        Lindsey A, Criswell LA. Genome-Wide Association Studies of SLE. What do these studies tell us 
        about disease mechanisms in lupus? The Rheumatologist 2011. 
        Liu K, Li QZ, Delgado-Vega AM, et al. Kallikrein genes are associated with lupus and glomerular 
        basement membrane-specific antibody-induced nephritis in mice and humans. J Clin Invest 
        2009;119:911–23. 
        Liu MF, Lee JH, Weng TH, et al. Clinical experience of 13 cases with severe pulmonary 
        haemorrhage in systemic lupus erythematosus with active nephritis. Scand J Rheumatol 
        1998;27:291–5. 
        Lopez R, Davidson JE, Beeby MD, et al. Lupus disease activity and the risk of subsequent organ 
        damage and mortality in a large lupus cohort. Rheumatology (Oxford) 2012;51:491–8. 
        Manger K, Manger B, Repp R, et al. Definition of risk factors for death, end stage renal disease, 
        and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus 
        erythematosus. Ann Rheum Dis 2002;61:1065–70. 
        Markle JG, Frank DN, Mortin-Toth S, et al. Sex differences in the gut microbiome drive hormone-
        dependent regulation of autoimmunity. Science 2013;339:1084–8. 
        McCollum CN, Sloan ME, Davison AM, et al. Ruptured hepatic aneurysm in systemic lupus 
        erythematosus. Ann Rheum Dis 1979;38:396–8. 
        McMahon M, Grossman J, Skaggs B, et al. Dysfunctional proinflammatory high-density lipoproteins 
        confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis 
        Rheum 2009;60: 2428–37. 
        Meroni PL, Schur PH. ANA screening: an old test with new recommendations. Ann Rheum Dis 
        2010;69:1420–22. 
        Namjou B, Kothari PH, Kelly JA, et al. Evaluation of the TREX1 gene in a large multi-ancestral 
        lupus cohort. Genes Immun 2011;12:270–9. 
        Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with 
        active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 
        2011;377:721–31. 
        Navarra SV, Leynes MS. Infections in systemic lupus erythematosus. Lupus 2010;19:1419–24. 
        Navarro-Zarza JE, Alvarez-Hernández E, Casasola-Vargas JC, et al. Prevalence of community-
        acquired and nosocomial infections in hospitalized patients with systemic lupus erythematosus. 
        Lupus 2010;19:43–8. 
        Nossent J, Kiss E, Rozman B, et al. Disease activity and damage accrual during the early disease 
        course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 
        2010;19:949–56. 
        O'Neill SG, Giles I, Lambrianides A, et al. Antibodies to apolipoprotein A1, high density lipoprotein 
        and C-reactive protein are associated with disease activity in patients with systemic lupus 
        erythematosus. Arthritis Rheum 2010;62:845–54. 
        Patel DR, Richardson BC. Dissecting complex epigenetic alterations in human lupus. Arthritis Res 
        Ther 2013;15:201. 
                                                                   4 
        Patel P, Werth V. Cutaneous lupus erythematosus: a review. Dermatol Clin 2002;20:373–385, v. 
        EULAR Secretariat | Seestrasse 240 | 8802 Kilchberg | Switzerland  
        T: +41 44 716 30 30 | F: +41 44 716 30 39  
        M: eular@eular.org | W: www.eular.org